. 2023 Oct 5;13:16823. doi: 10.1038/s41598-023-44062-1

Table 2.

Characteristics of the canine PAC cell lines.

	CPACd								CPACr
	p	AB4	AC12	AD4	AE3	BB4	CG11	DC10	p	AD4	AH4	BC9	BH12	CB2	DC3	DD10
Cellular morphology^a	E	E	E	E	I	E	E	M	E, I	E	M	I	I	E	I	E
Proliferative capasity^b	++	+	++	++	++	+++	++	++	++	+++	++	+++	++	++	+++	++
Expression of vimentin	+	++	+	−	++	−	+	+	+	+	+	++	+	−	++	+
EMT
Migration ability
(WHA)^c	+	++	+	±	++	±	++	+	+	+	±	++	+	++	++	+
(TMA) ^d	+	++	+	±	±	±	++	+	+	+	+	++	±	±	±	±
Invasion ability^d	±	++	±	±	±	±	+	±	+	+	±	++	±	±	±	±
CSC
Sphere forming ability ^e	±	+	±	+	++	+	+	±	+	+	+	±	++	+	+	±
Population of SP^f	±	+	±	±	±	±	++	++	±	+	±	±	±	±	±	++
Sensitivity to vinorelbine^g	+	±	±	+	++	++	±	+	++	++	++	+	++	+	++	+

EMT epithelial mesenchymal transition, CSC cancer stem cell, WHA wound-healing assay, TMA traswell migration assay, SP side population.

^aE: Epithelium, I: Intermediate between epithelium and mesenchmal, M: Mesenchyma.

^b+ : > 30 h of doubling time (DT), ++: 20–30 h of DT, +++: < 20 h of DT.

^c± : < 40% of wound closure, 40–70% of wound closure, ++: > 70% of wound closure.

^d ± : < 60 migration or invasion cells, +: 60–120 maigration or invasion cells, ++ ; > 120 migration or invasion cells.

^e ± : < 15 spheres, + : 15–30 spheres, ++; > 30 spheres.

^f ± : < 5% SP, + : 5–10% SP, ++; > 10 SP.

^g ± : > 1000 nM of IC50, +: 10–1000 nM of IC50, ++: < 10 nM of IC50.